TY - JOUR
T1 - Gut microbiota–derived short-chain fatty acids protect against the progression of endometriosis
AU - Chadchan, Sangappa B.
AU - Popli, Pooja
AU - Ambati, Chandrasekhar R.
AU - Tycksen, Eric
AU - Han, Sang Jun
AU - Bulun, Serdar E.
AU - Putluri, Nagireddy
AU - Biest, Scott W.
AU - Kommagani, Ramakrishna
N1 - Funding Information:
We thank Dr. Deborah J. Frank (Department of Obstetrics and Gynecology, Washington University) for assistance with manuscript editing and Alma Jackson (Department of Obstetrics and Gynecology, Washington University) for technical expertise. We also thank the Genome Technology Access Center in the Department of Genetics at Washington University School of Medicine for service with genomic analysis. The Center is partially supported by National Cancer Institute (NCI) Cancer Center Support Grant #P30 CA91842 to the Siteman Cancer Center and by Institute for Clinical and Translational Science (ICTS)/Clinical and Translational Sciences Award (CTSA) Grant# UL1TR002345 from the National Center for Research Resources, a component of the National Institutes of Health (NIH), and NIH Roadmap for Medical Research. This work was funded, in part, by National Institutes of Health/ National Institute of Child Health and Human Development grants R01HD102680, R01HD065435, and R00HD080742 to R Kommagani. The metabolomics core at Baylor College of Medicine is supported by the CPRIT Core Facility Support Award RP170005 and NCI Cancer Center Support Grant P30CA125123.
Publisher Copyright:
© 2021 Chadchan et al.
PY - 2021/10
Y1 - 2021/10
N2 - Worldwide, ~196 million are afflicted with endometriosis, a painful disease in which endometrial tissue implants and proliferates on abdominal peritoneal surfaces. Theories on the origin of endometriosis remained inconclusive. Whereas up to 90% of women experience retrograde menstruation, only 10% develop endometriosis, suggesting that factors that alter peritoneal environment might contribute to endometriosis. Herein, we report that whereas some gut bacteria promote endometriosis, others protect against endometriosis by fermenting fiber to produce short-chain fatty acids. Specifically, we found that altered gut microbiota drives endometriotic lesion growth and feces from mice with endometriosis contained less of short-chain fatty acid and n-butyrate than feces from mice without endometriosis. Treatment with n-butyrate reduced growth of both mouse endometriotic lesions and human endometriotic lesions in a pre-clinical mouse model. Mechanistic studies revealed that n-butyrate inhibited human endometriotic cell survival and lesion growth through G-protein–coupled receptors, histone deacetylases, and a GTPase activating protein, RAP1GAP. Our findings will enable future studies aimed at developing diagnostic tests, gut bacteria metabolites and treatment strategies, dietary supplements, n-butyrate analogs, or probiotics for endometriosis.
AB - Worldwide, ~196 million are afflicted with endometriosis, a painful disease in which endometrial tissue implants and proliferates on abdominal peritoneal surfaces. Theories on the origin of endometriosis remained inconclusive. Whereas up to 90% of women experience retrograde menstruation, only 10% develop endometriosis, suggesting that factors that alter peritoneal environment might contribute to endometriosis. Herein, we report that whereas some gut bacteria promote endometriosis, others protect against endometriosis by fermenting fiber to produce short-chain fatty acids. Specifically, we found that altered gut microbiota drives endometriotic lesion growth and feces from mice with endometriosis contained less of short-chain fatty acid and n-butyrate than feces from mice without endometriosis. Treatment with n-butyrate reduced growth of both mouse endometriotic lesions and human endometriotic lesions in a pre-clinical mouse model. Mechanistic studies revealed that n-butyrate inhibited human endometriotic cell survival and lesion growth through G-protein–coupled receptors, histone deacetylases, and a GTPase activating protein, RAP1GAP. Our findings will enable future studies aimed at developing diagnostic tests, gut bacteria metabolites and treatment strategies, dietary supplements, n-butyrate analogs, or probiotics for endometriosis.
UR - http://www.scopus.com/inward/record.url?scp=85117554342&partnerID=8YFLogxK
U2 - 10.26508/lsa.202101224
DO - 10.26508/lsa.202101224
M3 - Article
C2 - 34593556
AN - SCOPUS:85117554342
SN - 2575-1077
VL - 4
JO - Life Science Alliance
JF - Life Science Alliance
IS - 12
M1 - e202101224
ER -